Mesoderm Induction by Heterodimeric AP-1 (c-Jun and c-Fos) and Its Involvement in Mesoderm Formation through the Embryonic Fibroblast Growth Factor/Xbra Autocatalytic Loop during the Early Development of Xenopus Embryos*

Jaebong KimDagger , Jih-Jing LinDagger , Ren-He Xu§, and Hsiang-fu KungDagger

From the Dagger  Laboratory of Biochemical Physiology, Division of Basic Science, NCI-Frederick Cancer Research and Development Center, National Institutes of Health, Frederick, Maryland 21702-1201 and the § Intramural Research and Support Program, Science Applications International Corporation, Frederick, Maryland 21702-1201

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results & Discussion
References

We have previously demonstrated the involvement of AP-1/Jun in fibroblast growth factor (FGF) signaling by loss-of-function assay (Dong, Z., Xu, R.-H., Kim, J., Zhan, S.-N., Ma, W.-Y., Colburn, N. H., and Kung, H. (1996) J. Biol. Chem. 271, 9942-9946). Further investigations by gain-of-function are reported in this study. AP-1 transactivation activity was increased by the treatment of animal cap explants with FGF. Ectopic overexpression of two components of AP-1 (c-jun and c-fos together, but not alone) produced posteriorized embryos and induced mesoderm formation in animal cap explants, indicating that both AP-1 heterodimers are required for mesoderm induction. Since Ras/AP-1 functions downstream of FGF signaling, we then tested the involvement of Ras/AP-1 in mesoderm maintenance mediated by embryonic FGF/Xbra using dominant-negative mutants. Mesoderm maintenance mediated by embryonic FGF/Xbra was blocked by dominant-negative mutants of Ras/AP-1, and AP-1 enhanced the expression of Xbra. Further studies demonstrated the inhibition of Ras/AP-1-mediated mesoderm formation by dominant-negative mutants of the FGF receptor and Xbra. These results indicate that Ras/AP-1 and FGF/Xbra signals are involved in the mesoderm maintenance machinery and mesoderm formation through the synergistic action of the diversified signal pathways derived from the FGF/Xbra autocatalytic loop.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

In early vertebrate development, one of the most important events is the mesoderm-inducing process, and several mesoderm-inducing factors have been identified using an amphibian embryo system (1-6). In Xenopus, normal mesoderm formation in the embryo largely depends on FGF1 signaling (7-13). Experiments using the dominant-negative FGF receptor demonstrate that FGF signaling is required for posterior mesoderm formation in whole embryos (7, 8) and is also required for mesoderm induction in response to members of the transforming growth factor-beta superfamilies in animal cap culture (9-11). While two members of the FGF family, basic FGF (bFGF) (14, 15) and embryonic FGF (eFGF) (16), are present in mesoderm formation stages during early embryonic development, eFGF is more likely to be an endogenous inducer since it is efficiently secreted. bFGF, however, lacks a signal sequence for secretion. Xenopus eFGF is expressed maternally, and its expression increases significantly during gastrulation, suggesting its roles in mesoderm induction as well as mesoderm maintenance (17).

The components of the FGF signal transduction pathway required for mesoderm induction include Ras (18, 19), the protein kinase cascade of Raf (20), and the mitogen-activated protein kinase pathway (21-24). However, the downstream FGF signal(s) in the nucleus is largely unknown. One nuclear target of FGF signaling seems to be Xbra, a Xenopus homologue of Brachuary (25). Xbra has been used as a panmesodermal marker, and its expression is increased by treatment with mesoderm inducers including members of the FGF and transforming growth factor-beta families. While ectopic overexpression of Xbra is enough to induce the differentiated mesoderm, mesoderm formation in response to Xbra requires FGF signaling (13). Xbra and eFGF have been shown to be involved in the autoregulatory loop, in which Xbra induces the expression of eFGF, which is required for maintenance of the expression of Xbra (17).

In our laboratory, we have been interested in the roles of AP-1 during Xenopus early embryonic development (26, 27). We recently reported the involvement of AP-1/c-Jun in the FGF signaling pathway using dominant-negative jun (DN-jun) (26). Although the requirement for AP-1/c-Jun in FGF-induced mesoderm induction has been demonstrated by loss-of-function activity using DN-jun, these experiments cannot discriminate between the involvement of homodimeric and heterodimeric AP-1 in mesoderm induction. Also, we cannot conclude whether AP-1 is a necessary or a sufficient component in the pathway leading to mesoderm induction. Since the DNA-binding activity of the homodimeric Jun complex and the heterodimeric Jun-Fos complex to the AP-1 site is different in vitro (28) and the phenotypes of c-jun and c-fos null mutants are different in mammalian embryonic development (29-31), we examined the roles of c-Fos in the AP-1 complex in mesoderm formation during Xenopus early embryonic development.

Here, we report, for the first time, the microinjection of a heterodimeric AP-1 (c-jun/c-fos) transcription factor causing posteriorized embryos and leading to the induction of mesoderm in ectoderm explants from Xenopus embryos. In addition, we demonstrate that AP-1 (c-Jun/c-Fos) functions downstream of FGF signaling and is an essential component of the mesoderm maintenance machinery mediated by eFGF/Xbra. Furthermore, we found that FGF induces mesoderm formation and maintenance through the synergistic action of the diversified signals derived from the FGF/Xbra autocatalytic loop.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

DNA and RNA Preparation-- The c-jun cDNA was inserted into pGEM (28), and c-fos and antisense c-fos were subcloned into the pSP65 vector (32). The dominant-negative FGF receptor (DN-FR) (7), Xbra, and Xbra-Engrailed were inserted into the pSP64T vector (33, 34). Xbra-Engrailed (dominant-negative mutant of Xbra (DN-Xbra)) is a dominant-interfering Xbra generated by replacing the activation domain of Xbra with the repressor domain of the Drosophila Engrailed protein (34). DN-jun was subcloned into the pSP64TEN vector (26, 27). The constitutively active ras ([Val12]Ha-Ras) and dominant-negative ras (DN-ras; [Asn17]Ha-Ras) cDNAs were inserted into the pSP64 vector (18). Each of the cDNAs were linearized and used for in vitro synthesis of capped mRNA using an Ambion transcription kit in accordance with the manufacturer's instructions. The synthetic RNA was quantitated by ethidium bromide staining in comparison with a standard RNA.

Embryo Injection and Explant Culture-- Xenopus laevis embryos were obtained by in vitro fertilization (35). Developmental stages were designated according to Nieuwkoop and Faber (36). Embryos at the two-cell stage were injected in the animal pole with messenger RNA or cDNA as described in the figure legends. Animal caps were dissected from the injected embryos at stages 8.5-9 and cultured to various stages for further analysis as described in the figure legends.

Reverse Transcription-Polymerase Chain Reaction (RT-PCR)-- Total RNA was extracted from cultured explants with TRIzol reagent (Life Technologies, Inc.) following the manufacturer's instructions. RT-PCR was performed with a Superscript preamplification system (Life Technologies, Inc.). Primer sets and PCR conditions for Xbra, muscle actin, and EF-1alpha were as described previously (26, 36).

Analysis of AP-1 and NF-kappa B Activities in Animal Cap Culture-- AP-1- or NF-kappa B-luciferase plasmid DNA (26, 37, 38) was injected alone or together with the designated RNA into two blastomers of the two-cell stage embryo as described in the figure legends. After injection, the animal caps were excised from the embryos (stages 8.5-9) and cultured in the presence of different dosages of bFGF (2-100 ng/ml) until stages 10.5 and 13. AP-1-dependent luciferase activity in the animal cap explants was measured after homogenization in lysis buffer as described previously (26).

    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

bFGF Stimulates AP-1 Activity in Animal Cap Explants during Mesoderm Induction (Stage 10.5) and Mesoderm Maintenance (Stage 13) Stages-- Previously, we reported high levels of AP-1-dependent transactivation activity during Xenopus early embryonic development and inhibition of FGF-induced mesoderm formation in animal cap explants from embryos injected with DN-jun RNA (26). To determine whether AP-1 is a target transcription factor of the FGF signal, we performed the following experiments. Embryos were injected with AP-1- or NF-kappa B-luciferase reporter genes at the two-cell stage. The animal pole tissue was then dissected at stages 8.5-9 and incubated with different dosages of bFGF. The bFGF-treated animal caps were harvested at stages 10.5 and 13, and the luciferase activity in the animal caps was measured. The luciferase activity in the animal caps injected with the NF-kappa B-luciferase reporter gene was not affected by bFGF (Fig. 1B). On the other hand, the luciferase activity in the animal caps injected with the AP-1-luciferase reporter plasmid was increased 2-8-fold by bFGF treatment in a dose-dependent manner (Fig. 1A).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   AP-1 activation by bFGF. a, dose-dependent AP-1 activation by bFGF (2-100 ng). Ten pg of AP-1-luciferase construct was injected at the two-cell stage (26, 27), and the animal caps obtained from the embryos (stages 8.5-9) were cultured in the presence of different dosages of bFGF (2-100 ng/ml) until stages 10.5 and 13. b, effects of bFGF (2-100 ng) on NF-kappa B activity. The same procedure was followed as described for a, except that the NF-kappa B-luciferase reporter plasmid was used instead of the AP-1-luciferase construct. c, effect of bFGF and AP-1 on AP-1 activation. AP-1-luciferase reporter plasmids (10 pg) were coinjected with the mRNAs encoding c-Jun (0.5 ng) and c-Fos (0.5 ng) at the two-cell stage, and the luciferase activity was compared with the animal cap explants treated with 10 ng/ml bFGF. Treatment with bFGF was as described for a. The experiments were repeated three times with similar results. The data are presented as luciferase activity relative to the average luciferase activity in at least 20 animal caps. The luciferase activity in individual animal caps was measured after homogenization in 20 µl of lysis buffer as described previously (26).

In separate experiments, AP-1-luciferase reporter plasmids were coinjected with the mRNAs encoding c-Jun and c-Fos, and the luciferase activity was compared with the animal cap explants treated with bFGF. AP-1 RNA (c-jun/c-fos)-injected animal cap explants showed similar luciferase activity as bFGF-treated animal cap explants at stages 10.5 and 13 (Fig. 1C). The AP-1 activity in FGF-treated animal cap explants was inhibited by DN-ras RNA injection (data not shown), suggesting that FGF signals through the Ras pathway for AP-1 activation. However, AP-1-dependent luciferase activity was not affected in animal cap explants injected with noggin or dominant-negative BMP-4 receptor mRNA (data not shown), which caused neuralization in the ectoderm.

Heterodimeric AP-1 Induces Mesoderm Formation-- The mesoderm-inducing activity of AP-1 (c-jun and c-fos) was then examined by injection of RNA encoding c-Jun and/or c-Fos at the two-cell stage. The animal pole tissue was dissected at the blastula stage (stages 8.5-9) and incubated until the animal cap explants were harvested. Injection of beta -galactosidase, c-jun, or c-fos RNA alone or c-jun plus antisense c-fos RNA did not induce any morphological changes in the animal cap explants cultured until the tadpole stage (Fig. 2a, panel A). On the other hand, animal caps from embryos injected with c-jun and c-fos RNAs together showed morphological changes (the animal caps were swollen and elongated) similar to those induced by FGF treatment in a dose-dependent manner (Fig. 2a, panels B-D).


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 2.  

Mesoderm induction in blastula animal caps by AP-1 (c-jun/c-fos). a, morphological changes in animal cap explants. X. laevis embryos were obtained by in vitro fertilization (35). Embryos at the two-cell stage were injected in the animal pole with mRNAs of control beta -galactosidase (1 ng), c-jun (1 ng), c-fos (1 ng), or c-jun (1 ng) plus antisense c-fos (1 ng) (panel A); c-jun/c-fos (0.25 ng each) (B); c-jun/c-fos (0.5 ng each) (C); or c-jun/c-fos (1 each ng) (D). c-jun, c-fos, and antisense c-fos were derived from rat clones (28, 32). Animal caps were dissected from the injected embryos at stages 8.5-9 and cultured until stage 30 for the picture. The experiment was repeated three times in over 120 embryos with similar results. Developmental stages were designated according to Nieuwkoop and Faber (36). b, molecular markers of mesoderm induction induced by AP-1 (c-jun and c-fos together). Embryos were injected, and animal caps were dissected and cultured as described for a. RNA was isolated from animal caps injected with the following: lane 1, beta -galactosidase (beta -gal; 1 ng); lane 2, c-jun (1 ng); lane 3, c-fos (1 ng); lane 4, c-jun (1 ng) plus antisense c-fos (1 ng); lane 5, c-jun (1 ng) plus sense c-fos (1 ng); lane 6, control (No Injection). The RNA was analyzed by RT-PCR (26, 35) to determine the expression of the molecular markers Xbra and EF-1alpha with stage 11 animal caps and muscle actin and EF-1alpha with stage 30 animal caps. Embryos at equivalent stages were used as a positive control (lane 7), and the same embryo sample processed for RT-PCR in the absence of reverse transcriptase (No RT) was used as a negative control (lane 8). c, immunohistochemical analysis of animal caps generated by injection of beta -galactosidase RNA (1 ng) (panel A) or AP-1 RNAs (1 ng of c-jun and 1 ng of c-fos) (panel B) and by treatment with bFGF (100 ng/ml) (panel C). Animal caps were harvested and sectioned at stage 30. The slides were then fixed and stained with specific antibody to muscle actin. Panels B and C show the muscle actin-stained section (dark brown color) with unorganized muscle tissue. Panel A shows an unstained section with a typical epidermis structure. The animal caps from embryos injected with c-jun (1 ng), c-fos (1 ng), or c-jun (1 ng) plus antisense c-fos (1 ng) were examined with the same procedure as described for panels A, B, and C of Fig. 2c. Typical epidermis structures similar to beta -galactosidase-treated animal caps were found. d, dose-dependent mesoderm formation as measured by the expression of Xbra (stage 11) and actin (stage 24). Injection of c-jun alone (0.5-4 ng in lanes 1-4 in the upper panels), c-jun + c-fos (0.5-4 ng; 0.5 ng = 0.25 ng of each in lane 1, 1 ng = 0.5 ng of each in lane 2, 2 ng = 1 ng of each in lane 3, and 4 ng = 2 ng of each in lane 4 in the lower panels), and beta -galactosidase (lane 5). Lane 6 is the positive control of the embryo, and lane 7 is the negative control with no reverse transcriptase. Embryos were injected, and animal caps were dissected and cultured as described for a. RT-PCR was performed as described for b. Expression of EF-1alpha was used as a control for equal loading of reverse transcriptase samples.

To confirm the mesoderm induction in animal caps, we examined early and late molecular markers for mesoderm by RT-PCR. Xbra, an immediate-early marker for mesoderm, and muscle-specific actin, a late marker for mesodermal differentiation, were expressed in AP-1 (c-jun/c-fos)-injected caps, but not in beta -galactosidase, c-fos, or c-jun RNA-injected caps or in c-jun plus antisense c-fos RNA-injected caps (Fig. 2b). Immunohistochemical analysis showed that the animal cap injected with c-jun and c-fos together generated unorganized muscle tissues similar to the tissues generated by treatment with bFGF. Actin was detected by specific antibody to muscle actin in the sections of c-jun- and c-fos-injected animal cap samples and bFGF (100 ng)-treated samples, but not in the other samples (Fig. 2c). For mesoderm formation, injection of 0.5 ng of c-jun RNA and 0.5 ng of c-fos RNA together was sufficient to induce Xbra at the early stage (stage 11) and muscle actin at the later stage (stage 24) in ectoderm cells. However, animal cap explants injected with up to 4 ng of c-jun alone did not show any detectable morphological changes or increased expression of the mesodermal markers Xbra and actin. A very small amount of Xbra was detected in c-jun-injected animal cap explants as determined by RT-PCR (Fig. 2d).

These results clearly demonstrate that heterodimeric AP-1 (c-jun and c-fos) is sufficient to induce mesoderm in animal cap explants, similar to FGF and its signal molecules, Ras/Raf/mitogen-activated protein kinase, but homodimeric AP-1 (c-Jun) is not able to induce mesoderm. The previous results (26) for the AP-1/Jun involvement in FGF-mediated mesoderm induction by loss-of-function assay with DN-jun were possibly caused by the blocking of heterodimeric AP-1 activity. Although we have demonstrated the requirement of both c-Jun and c-Fos for mesoderm formation, it remains to be determined whether the requirement of c-Jun/c-Fos can be replaced by other members of the Jun/Fos families. In the present study, we have focused only on the direct roles of c-Jun/c-Fos.

AP-1 Causes Posteriorized Embryos-- Whole embryos injected with beta -galactosidase, c-jun, or c-fos RNA alone at the two-cell stage did not show any morphological changes (data not shown). Another transcription factor (AP-2 RNA) was also injected, and no morphological change was observed (data not shown). However, c-jun and c-fos RNAs injected together caused morphological changes in a dose-dependent manner (Fig. 3a). Embryos injected with AP-1 mRNAs (0.5 ng of c-jun and 0.5 ng of c-fos) at the two-cell stage developed normally through the mid-gastrula stage, but the blastopore closure was delayed (Fig. 3b, panel B). A similar phenotype of abnormal gastrulation defects was observed with injection of other mesoderm inducers, Xbra (0.5 ng) or ras RNA (1 ng) (Refs. 12 and 33 and data not shown). Injection of low doses of AP-1 RNAs (0.125 ng of c-jun and 0.125 ng of c-fos) caused an enlarged proctodeum at the posterior part of the embryo at the tadpole stage, which is a typical phenotype of CSKA-eFGF plasmid-injected embryos (17). The embryos injected with AP-1 exhibited a posteriorized phenotype with diminished anterior structures including cement gland and forebrain. The extent of morphological changes depends greatly on AP-1 dosages up to 2 ng. Histological analysis showed that unorganized muscle-like structure accumulated in the posterior part of AP-1-injected embryos (data not shown). Interestingly, in animal cap explants excised from embryos coinjected with AP-1 and chordin, posterior neural markers were induced.2 The caudalization of neural tissues with FGF or Xbra has recently been reported (39-41), indicating that AP-1 is involved in a broad range of FGF activities.


View larger version (82K):
[in this window]
[in a new window]
 
Fig. 3.   Morphological changes in whole embryos induced by ectopic expression of AP-1 (c-jun and c-fos). a, dose-dependent morphological changes in whole embryos by injection of AP-1 (0.125-1 ng of c-jun/c-fos). Panel A, 0.125 ng each; panel B, 0.25 ng each; panel C, 0.5 ng each; panel D, 1 ng each. The RNAs of c-jun and c-fos were injected into the animal pole of the two-cell stage embryos. The injected embryos were allowed to develop until the tadpole stage. The embryos injected with AP-1 show posteriorized phenotypes with diminished anterior structures including cement gland and forebrain. The extent of morphological changes was dose-dependent. In the same experiments, the morphological changes were never observed in embryos injected with beta -galactosidase (1 ng), c-jun (1-4 ng), c-fos (1-4 ng), or c-jun (1 ng) plus antisense c-fos (1 ng). b, gastrulation defect induced by injection of AP-1. The blastopore of an embryo injected with 1 ng of beta -galactosidase was closed (panel A). The embryos injected with AP-1 (0.5 ng of c-jun and 0.5 ng of c-fos) developed normally through the blastula and early gastrula stages (not shown). However, the blastopore failed to close as shown by a round circle in the picture (panel B). Pictures were taken at stage 15. c, effects on embryonic development of injection of AP-1 into the VMZ or DMZ. AP-1 mRNAs (0.5 ng of c-jun and 0.5 ng of c-fos) were injected at the four-cell stage into the DMZ or VMZ. Injection of AP-1 into the VMZ caused a minor posterior defect (panel A, lower picture) compared with a normal tadpole (panel A, upper picture). In contrast, AP-1 injection into the DMZ of embryos caused a gastrulation delay and severe defects in body patterning including lack of head structure (~10% embryos) (panel B, lower picture).

Injection of AP-1 RNAs (c-jun and c-fos) into the dorsal marginal zone (DMZ) or the ventral marginal zone (VMZ) in embyros at the four-cell stage resulted in different phenotypes (Fig. 3c). Injection of AP-1 into the VMZ caused a minor posterior defect with normal head structure (Fig. 3c, panel A). However, injection of AP-1 RNAs into the DMZ caused a gastrulation delay and consequently more severe defects in the anterior, including lack of a head structure, but rather normal posterior structure (Fig. 3c, panel B).

While this work was in progress, an implantation experiment with eFGF beads in gastrulas was published (42). When an eFGF bead was implanted into the dorsal lip of a stage 11.5 embryo, it resulted in the loss of eyes and forebrain as well as other anterior structures, with a normal proctodeum in the tail bud-stage embryo. However, when an eFGF bead was implanted into the ventral lip at stage 11.5, the embryos developed normally, including the head structure. The results were similar to those of the present study of AP-1 (see above). The similarity in morphological changes further suggests that AP-1 (c-Jun/c-Fos) may be a mediator in the FGF signaling pathway.

Ras/AP-1 Functions Downstream of FGF Signaling in Mesoderm Formation-- AP-1 transactivation activity in animal cap explants was increased by treatment with bFGF in culture media. Furthermore, AP-1 induced mesoderm formation and the expression of Xbra and muscle actin similar to bFGF. These results suggest that AP-1 may be a target molecule of FGF signaling in the nucleus. Although Xenopus bFGF produced from the injected mRNA has a potent mesodermalizing effect on animal hemisphere cells, bFGF has no signal sequence that may be necessary for cell-cell signaling events such as mesoderm induction. Furthermore, virtually no phenotypic change by bFGF treatment is observed in intact embryos (43). In contrast to bFGF, eFGF plays an important role in maintaining the properties of mesoderm in the gastrulas of Xenopus embryos in addition to its mesoderm-inducing activity during the blastula stages. The expression of eFGF increases significantly during gastrulation. In addition, eFGF caused similar morphological changes in whole embryos (posteriorization) as observed with AP-1 mRNA injection. Although Xbra and eFGF have been reported to require each other for mesoderm maintenance (13, 17), the roles of Ras/AP-1 have not been clearly demonstrated in mesoderm maintenance mediated by eFGF/Xbra. Therefore, it is interesting to test whether signaling components of FGF (Ras/AP-1) are involved in mesoderm maintenance mediated by the FGF/Xbra autocatalytic loop.

The injection of Xbra RNA or the CSKA-eFGF plasmid into animal caps caused morphological changes (swelling and elongation) as shown in Fig. 4a. The CSKA-eFGF plasmid becomes transcriptionally active after mid-blastula transition (44), and eFGF mRNA does not accumulate until stage 10 (17). The animal cap explants start to lose competence for mesoderm induction in response to bFGF after stage 10. However, the animal cap injected with the CSKA-eFGF plasmid showed a consistently potent mesoderm-forming ability, indicating that the period of competence of ectoderm cells for mesoderm induction might be longer than what is usually expected.


View larger version (86K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of eFGF- and Xbra-induced mesoderm induction by DN-ras and DN-jun. a, reversal of CSKA-eFGF- or Xbra-induced morphological changes in animal caps by DN-jun at stage 13. Animal caps from embryos injected with 25 pg of CSKA-eFGF plasmid and 1 ng of beta -galactosidase RNA (panel A), 25 pg of CSKA-eFGF plasmid and 1 ng of DN-jun RNA (panel B), 0.5 ng of Xbra RNA and 1 ng of beta -galactosidase RNA (panel C), and 0.5 ng of Xbra RNA and 1 ng of DN-jun RNA (panel D) were dissected at stages 8.5-9 and cultured until stage 13, when the pictures were taken. b, inhibition of eFGF- and Xbra-induced actin expression by DN-ras and DN-jun. Animal caps were dissected and cultured until stage 24 as described for Fig. 2a. RT-PCR was performed with the RNAs isolated from animal caps injected with the following: lane 1, Xbra (0.5 ng) and beta -galactosidase (beta -gal; 1 ng); lane 2, Xbra (0.5 ng) and DN-ras (1 ng); lane 3, Xbra (0.5 ng) and DN-jun (1 ng); lane 4, CSKA-eFGF (25 pg) and beta -galactosidase (1 ng); lane 5, CSKA-eFGF (25 pg) and DN-ras (1 ng); lane 6, CSKA-eFGF (25 pg) and DN-jun (1 ng); lane 7, beta -galactosidase (1 ng). Embryos at equivalent stages were used as a positive control (lane 8), and the same embryo sample without reverse transcriptase (No RT) was used as a negative control (lane 9) as described for Fig. 2b.

Coinjection of RNAs encoding DN-Ras significantly reduced elongation movements of animal cap explants in response to eFGF or Xbra during the gastrulation stages (data not shown), suggesting that maintenance of mesoderm depends on the downstream FGF signal, Ras. As expected, coinjection of DN-jun with Xbra or eFGF inhibited elongation movements similar to DN-ras (Fig. 4a). Since the maintenance of mesoderm in the gastrulating embryo is crucial for the formation of differentiated mesoderm-like muscle (45), we examined the expression of muscle actin. Animal caps derived from coinjection of DN-ras or DN-jun with eFGF or Xbra were cultured until the tadpole stage and assayed for muscle actin expression by RT-PCR. Consistent with the morphological data, DN-ras and DN-jun significantly inhibited the expression of muscle actin in animal caps derived from coinjected samples (Fig. 4b). Since Ras/AP-1 activates Xbra expression, and Xbra is able to induce the differentiated mesoderm, it was unclear whether Ras/AP-1 was involved only in mesoderm induction or also in later events after mesoderm induction. The results suggest that Ras and AP-1 are involved in mesoderm maintenance in addition to mesoderm induction.

AP-1-induced Mesoderm Is Inhibited by DN-Xbra-- FGF/Ras/AP-1 had an activity to induce an early mesodermal marker, Xbra. While ectopic overexpression of Xbra itself is enough to generate the differentiated mesoderm, Xbra still requires endogenous FGF/Ras/AP-1 signals for mesoderm maintenance and differentiated mesoderm formation. On the other hand, FGF-mediated mesoderm formation and maintenance are dependent on Xbra. Since AP-1 was found to be involved in the mesoderm maintenance machinery mediated by eFGF/Xbra, we examined whether Xbra is required for AP-1-mediated mesoderm formation. AP-1-mediated mesoderm formation was abolished by coinjection of DN-Xbra. DN-Xbra inhibited the expression of muscle actin as well as Xbra itself in animal caps derived from coinjected samples (Fig. 5). The RT-PCR product of Xbra shown in Fig. 5 has been designed not to detect injected DN-Xbra. The results indicate that intact Xbra is required for its own expression and mesoderm induction. Furthermore, the effect of DN-Xbra was not reversed by AP-1. Although it remains to be investigated how Xbra regulates its own transcription, we postulate that Xbra is required to keep the mesoderm character of the tissue and that DN-Xbra blocks the competence of the animal cap for mesoderm induction. We extended the mesoderm maintenance machinery of eFGF/Xbra to include Ras/AP-1, and the blocking of one of the components is enough to abolish the machinery of mesoderm formation, suggesting that positive feedback is necessary to maintain mesoderm (see Fig. 7).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 5.   Inhibition of AP-1-induced mesoderm induction by coinjection of DN-Xbra. Embryos were injected as described below, and animal caps were dissected and cultured as described for Fig. 2a. RNA was isolated from animal caps injected with the following: lane 1, c-jun (1 ng) plus c-fos (1 ng); lane 2, c-jun (1 ng), c-fos (1 ng), and DN-Xbra (1 ng); lane 3, DN-Xbra (1 ng); lane 4, beta -galactosidase (beta -gal; 2 ng). The RNA was analyzed by RT-PCR as described for Fig. 2b (Xbra and EF-1alpha with stage 11 animal caps and muscle actin and EF-1alpha with stage 30 animal caps). Embryos at equivalent stages were used as a positive control (lane 5), and the same embryo sample processed for RT-PCR in the absence of reverse transcriptase (No RT) was used as a negative control (lane 6) as described for Fig. 2b.

Mesoderm Formation by FGF Signaling Is a Synergistic Action of Diversified Signal Pathways-- FGF and Xbra require each other for mesoderm formation and maintenance, and the downstream signal molecules of the FGF receptor are involved in these events. However, it is not clear whether FGF signals for mesoderm induction and maintenance through a linear array of signals or through the synergistic action of the diversified signals. These two possibilities were examined by coinjecting an activated form of Ras with DN-FR. Constitutively active ras was coinjected with DN-FR, and the animal cap explants were analyzed. The elongation movement of animal cap explants caused by the overexpression of the constitutively active form of ras was inhibited by coinjection of DN-FR (Fig. 6a). Consistent with morphological data, the expression level of the early mesodermal marker (Xbra) and the differentiated mesodermal marker (muscle actin) was reduced or totally abolished by coinjection of DN-FR (Fig. 6b). This result suggests that Ras-mediated mesoderm formation requires endogenous FGF signaling and that FGF triggers at least two different signals including Ras for mesoderm formation. Consistently, AP-1-induced mesoderm formation was also inhibited by coinjection of DN-FR (Fig. 6c). Furthermore, AP-1-induced mesoderm formation was inhibited by coinjection of DN-ras (Fig. 6c). Our results suggest that mesoderm formation induced by FGF signaling is the synergistic action of the diversified signals. Based on these results, a model is proposed. As shown in Fig. 7, the signals derived from the FGF/Xbra autocatalytic loop contribute synergistically to the formation of mesoderm. The blocking of any signals by dominant-negative mutants resulted in inhibited mesoderm formation. In this paper, we show, for the first time, that heterodimeric AP-1 (c-Jun/c-Fos) induces mesoderm formation in animal cap explants of Xenopus embryos. Additionally, we found that eFGF- or Xbra-mediated mesoderm maintenance was dependent on the downstream signals of FGF, Ras, and AP-1. Also, AP-1-mediated mesoderm formation required FGF/ras/Xbra, and Xbra expression was activated by AP-1. Furthermore, we found that FGF induced mesoderm formation and maintenance through the synergistic action of the diversified signals derived from the FGF/Xbra autocatalytic loop.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 6.   Requirement of endogenous signaling in Ras- or AP-1-mediated mesoderm formation. a, morphological reversion of activated Ras-mediated mesoderm formation by DN-FR at stage 13. Animal caps from embryos injected with beta -galactosidase RNA (1 ng) (panel A), constitutively active ras RNA (1 ng) (panel B), and constitutively active ras RNA (1 ng) and DN-FR RNA (1 ng) (panel C) were dissected at stages 8.5-9 and cultured until stage 13, when the pictures were taken. b, inhibition of Ras-mediated mesoderm formation by DN-FR. Embryos were injected as described below, and animal caps were dissected and cultured as described for Fig. 2a. RNA was isolated from animal caps injected with the following: lane 1, ras (1 ng) and DN-FR (1 ng); lane 2, ras (1 ng) and beta -galactosidase (beta -gal; 1 ng); lane 3, beta -galactosidase (2 ng). The RNA was analyzed by RT-PCR as described for Fig. 2b. 6, inhibition of AP-1-mediated mesoderm formation by DN-FR or DN-ras. Embryos were injected, dissected, and cultured as described for Fig. 2a. RT-PCR was performed as described for Fig. 2b with animal caps injected with the following: lane 2, c-jun (1 ng) and c-fos (1 ng); lane 3, c-jun (1 ng), c-fos (1 ng), and DN-FR (1 ng); lane 4, c-jun (1 ng), c-fos (1 ng), and DN-ras (1 ng); lane 5, beta -galactosidase (2 ng); lane 6, DN-FR (1 ng); lane 7, DN-ras (1 ng). Lane 1 is the non-injected control. Xbra and EF-1alpha were measured with stage 11 animal caps, and muscle actin and EF-1alpha were measured with stage 24 animal caps. Embryos at equivalent stages were used as a positive control (lanes 4 and 8 in b and c, respectively), and the same embryo sample processed for RT-PCR in the absence of reverse transcriptase (No RT) was used as a negative control (lanes 5 and 9, respectively) as described for Fig. 2b.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 7.   Proposed model for mesoderm formation mediated by the FGF/Xbra autoregulatory loop. Ras/AP-1 is involved in the FGF/Xbra autoregulatory loop, and Xbra is activated by AP-1. Diversified signals derived from each component (FGF/Ras/AP-1/Xbra) of the autoregulatory loop are required for mesoderm induction and maintenance. The blocking of any one component of the loop by the dominant-negative mutants results in the inhibition of mesoderm formation.

    ACKNOWLEDGEMENTS

We thank Dr. T. Curran for c-jun and sense and antisense c-fos cDNAs; Drs. F. L. Conlon, V. Cunliffe, and J. C. Smith for the Xbra and Xbra-Engrailed cDNAs; Drs. H. V. Isaacs and J. M. Slack for the eFGF plasmid; Drs. E. Amaya and M. Kirschner for the dominant-negative FGF receptor cDNA; and Drs. M. Whitman and D. A. Melton for the constitutively active ras ([Val12]Ha-Ras) and dominant-negative ras ([Asn17]Ha-Ras) cDNAs. We also thank Dr. D. L. Newton for synthesis of the oligonucleotide primers, Drs. Nancy H. Colburn and Ira Daar for helpful comments on the manuscript, and Annie Rogers for editing the manuscript.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 301-846-5703; Fax: 301-846-6863; E-mail: Kungh{at}mail.ncifcrf.gov.

1 The abbreviations used are: FGF, fibroblast growth factor; bFGF, basic fibroblast growth factor; eFGF, embryonic fibroblast growth factor; DN-jun, dominant-negative mutant of jun; DN-FR, dominant-negative mutant of the FGF receptor; DN-Xbra, dominant-negative mutant of Xenopus brachuary (Xbra-Engrailed); DN-ras, dominant-negative mutant of ras; RT-PCR, reverse transcription-polymerase chain reaction; EF-1alpha , elongation factor-1alpha ; DMZ, dorsal marginal zone; VMZ, ventral marginal zone.

2 J. Kim and H.-f. Kung, unpublished data.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

  1. Kimelman, D., Christian, J. L., and Moon, R. T. (1992) Development (Camb.) 116, 1-9[Abstract/Free Full Text]
  2. Smith, J. C. (1993) EMBO J. 12, 4463-4470[Medline] [Order article via Infotrieve]
  3. Slack, J. M. W. (1994) Curr. Biol. 4, 116-126[Medline] [Order article via Infotrieve]
  4. Kessler, D. S., and Melton, D. A. (1994) Science 266, 596-604[Medline] [Order article via Infotrieve]
  5. Smith, J. C. (1987) Development (Camb.) 99, 3-14[Abstract]
  6. Whitman, M., and Melton, D. A. (1989) Science 244, 803-806[Medline] [Order article via Infotrieve]
  7. Amaya, E., Musci, T. J., and Kirschner, M. W. (1991) Cell 66, 257-270[Medline] [Order article via Infotrieve]
  8. Amaya, E., Stein, P. A., Musci, T. J., Kirschner, M. W. (1993) Development (Camb.) 118, 477-487[Abstract/Free Full Text]
  9. Cornell, R. A., and Kimelman, D. (1994) Development (Camb.) 120, 453-462[Abstract/Free Full Text]
  10. LaBonne, C., and Whitman, M. (1994) Development (Camb.) 120, 463-472[Abstract/Free Full Text]
  11. Cornell, R. A., Musci, T. J., and Kimelman, D. (1995) Development (Camb.) 121, 2429-2437[Abstract/Free Full Text]
  12. Northrop, J., Woods, A., Seger, R., Suzuki, A., Ueno, N., Krebs, E., and Kimelman, D. (1995) Dev. Biol. 172, 242-252[CrossRef][Medline] [Order article via Infotrieve]
  13. Schulte-Merker, S., and Smith, J. C. (1955) Curr. Biol. 5, 62-67
  14. Kimelman, D., Abraham, J. A., Haaparanta, T., Palisi, T. M., Kirschner, M. (1988) Science 242, 1053-1056[Medline] [Order article via Infotrieve]
  15. Slack, J. M. W., and Isaacs, H. V. (1989) Development (Camb.) 105, 147-153[Abstract]
  16. Isaacs, H. V., Tannahill, D., and Slack, J. M. W. (1992) Development (Camb.) 114, 711-720[Abstract]
  17. Isaacs, H. V., Pownall, M. E., and Slack, J. M. W. (1994) EMBO J. 13, 4469-4481[Abstract]
  18. Whitman, M., and Melton, D. A. (1992) Nature 357, 252-255[CrossRef][Medline] [Order article via Infotrieve]
  19. Marshall, C. J. (1995) Cell 80, 179-185[Medline] [Order article via Infotrieve]
  20. MacNicol, A. M., Muslin, A. J., and Williams, L. T. (1993) Cell 73, 571-583[Medline] [Order article via Infotrieve]
  21. Graves, L. M., Northrop, L. J., Potts, B. C., Krebs, E. G., Kimelman, D. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1662-1666[Abstract]
  22. Gotoh, Y., Masuyama, N., Suzuki, A., Ueno, N., and Nishida, E. (1995) EMBO J. 14, 2491-2498[Abstract]
  23. LaBonne, C., Burke, B., and Whitman, M. (1995) Development (Camb.) 121, 1475-1486[Abstract/Free Full Text]
  24. Umbhauer, M., Marshall, C. J., Mason, C. S., Old, R. W., Smith, J. C. (1995) Nature 376, 58-62[CrossRef][Medline] [Order article via Infotrieve]
  25. Smith, J. C., Price, B. M. J., Green, J. B. A., Weigel, D., Herrmann, B. G. (1991) Cell 67, 79-87[Medline] [Order article via Infotrieve]
  26. Dong, Z., Xu, R.-H., Kim, J., Zhan, S.-N., Ma, W.-Y., Colburn, N. H., Kung, H.-f. (1996) J. Biol. Chem. 271, 9942-9946[Abstract/Free Full Text]
  27. Xu, R.-H., Dong, Z., Maeno, M., Kim, J., Suzuki, A., Ueno, N., Sredni, D., Colburn, N. H., Kung, H.-f. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 834-838[Abstract/Free Full Text]
  28. Rauscher, F. J., III, Voulalas, P. J., Franza, B. R., Jr., Curran, T. (1988) Genes Dev. 2, 1687-1699[Abstract]
  29. Johnson, R. S., van Lingen, B., Papaioannou, V. E., Spiegelman, B. M. (1993) Genes Dev. 7, 1309-1317[Abstract]
  30. Johnson, R. S., Spiegelman, B. M., and Papaioannou, V. (1992) Cell 71, 577-586[Medline] [Order article via Infotrieve]
  31. Wang, Z. Q., Ovitt, C., Grigoriadis, A. E., Mohle-Steinlein, U., Ruther, U., Wagner, E. F. (1992) Nature 360, 741-745[CrossRef][Medline] [Order article via Infotrieve]
  32. Curran, T., Gordon, M. B., Rubino, K. L., Sambucetti, L. (1987) Oncogene 2, 79-84[Medline] [Order article via Infotrieve]
  33. Cunliffe, V., and Smith, J. C. (1992) Nature 358, 427-430[CrossRef][Medline] [Order article via Infotrieve]
  34. Conlon, F. L., Sedgwick, S. G., Weston, K. M., Smith, J. C. (1996) Development (Camb.) 122, 2427-2435[Abstract/Free Full Text]
  35. Xu, R.-H., Kim, J., Taira, M., Zhan, S.-N., Sredni, D., and Kung, H.-f. (1995) Biochem. Biophys. Res. Commun. 212, 212-219[CrossRef][Medline] [Order article via Infotrieve]
  36. Nieuwkoop, P. D., and Faber, J. (1967) Normal Table of Xenopus laevis, 2nd Ed, North-Holland, Amsterdam
  37. Nordeen, S. K. (1988) BioTechniques 6, 444-447 [Medline] [Order article via Infotrieve]
  38. Dong, Z., Birrer, M. J., Watts, R. G., Matrisian, L. M., Colburn, N. H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 609-613[Abstract]
  39. Cox, W. G., and Hemmati-Brivanlou, A. (1995) Development (Camb.) 121, 4349-4358[Abstract/Free Full Text]
  40. Taira, M., Saint-Jeannet, J.-P., and Dawid, I. B. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 895-900[Abstract/Free Full Text]
  41. Xu, R.-H., Kim, J., Taira, M., Sredni, D., and Kung, H.-f. (1997) J. Neurosci. 17, 6892-6898[Abstract/Free Full Text]
  42. Pownall, M. E., Tucker, A. S., Slack, J. M. W., Isaacs, H. V. (1996) Development (Camb.) 122, 3881-3892[Abstract/Free Full Text]
  43. Kimelman, D., and Mass, A. (1992) Development (Camb.) 114, 261-269[Abstract]
  44. Harland, R., and Misher, L. (1988) Development (Camb.) 102, 341-359
  45. Kroll, K. L., and Amaya, E. (1996) Development (Camb.) 122, 3173-3183[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.